专利检索 ap:"Odile Levy" 第 1 页

1.

发明授权
Engineered polypeptides having enhanced duration of action with reduced immunogenicity 有权
标题翻译：具有增强的作用持续时间并具有降低的免疫原性的工程化多肽

公开(公告)号：US09382304B2

公开(公告)日：2016-07-05

申请号：US14129815

申请日：2012-07-03

申请人： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Manoj P. Samant , Abhinandini Sharma , Lala Mamedova , Esther Odile Levy , Caroline Ekblad

发明人： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Manoj P. Samant , Abhinandini Sharma , Lala Mamedova , Esther Odile Levy , Caroline Ekblad

IPC分类号： C07K14/605 , A61K47/48 , C12N15/62

CPC分类号： C07K14/605 , A61K47/65 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/70

摘要： Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.

摘要翻译： 提供化合物尤其具有良好的作用持续时间，高效力和/或方便的给药方案，包括口服给药和降低的免疫原性。所述化合物是结合一种或多种生物活性多肽的白蛋白结合结构域的工程多肽。还提供了治疗疾病和病症的药物组合物和方法，包括肥胖和超重，糖尿病，血脂异常，高脂血症，阿尔茨海默病，脂肪肝疾病，短肠综合症，帕金森病和心血管疾病。

2.

发明申请
ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION WITH REDUCED IMMUNOGENICITY 有权
标题翻译：具有减少免疫原性的增强作用时间的工程多糖

公开(公告)号：US20140235535A1

公开(公告)日：2014-08-21

申请号：US14129815

申请日：2012-07-03

申请人： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Manoj P. Samant , Abhinandini Sharma , Lala Mamedova , Esther Odile Levy , Caroline Ekblad

发明人： Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Manoj P. Samant , Abhinandini Sharma , Lala Mamedova , Esther Odile Levy , Caroline Ekblad

IPC分类号： C07K14/605

CPC分类号： C07K14/605 , A61K47/65 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/70

摘要： Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.

摘要翻译： 提供化合物尤其具有良好的作用持续时间，高效力和/或方便的给药方案，包括口服给药和降低的免疫原性。所述化合物是结合一种或多种生物活性多肽的白蛋白结合结构域的工程多肽。还提供了治疗疾病和病症的药物组合物和方法，包括肥胖和超重，糖尿病，血脂异常，高脂血症，阿尔茨海默病，脂肪肝疾病，短肠综合症，帕金森病和心血管疾病。

3.

发明申请
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus 审中-公开
标题翻译：新型肽作为丙型肝炎病毒的NS3-丝氨酸蛋白酶抑制剂

公开(公告)号：US20050059606A1

公开(公告)日：2005-03-17

申请号：US10934141

申请日：2004-09-03

申请人： Anil Saksena , Viyyoor Girijavallabhan , Raymond Lovey , Edwin Jao , Ashok Arasappan , Tejal Parekh , Patrick Pinto , Frank Bennett , Jinping McCormick , Haiyan Wang , Russell Pike , Stephane Bogen , Yi-Tsung Liu , F. Njoroge , Ashit Ganguly , Terence Brunck , Scott Kemp , Odile Levy , Marguerita Lim-Wilby

发明人： Anil Saksena , Viyyoor Girijavallabhan , Raymond Lovey , Edwin Jao , Ashok Arasappan , Tejal Parekh , Patrick Pinto , Frank Bennett , Jinping McCormick , Haiyan Wang , Russell Pike , Stephane Bogen , Yi-Tsung Liu , F. Njoroge , Ashit Ganguly , Terence Brunck , Scott Kemp , Odile Levy , Marguerita Lim-Wilby

IPC分类号： C12N9/99 , A61K31/7052 , A61K38/00 , A61K38/21 , A61K38/55 , A61K45/00 , A61P1/16 , A61P31/12 , A61P31/14 , A61P35/00 , A61P43/00 , C07K7/00 , C07K7/02 , C07K7/06 , A61K38/08

CPC分类号： C07K7/06 , A61K38/00 , C07K7/02

摘要： The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such peptides as well as methods of using them to treat disorders associated with the HCV protease.

摘要翻译： 本发明公开了具有HCV蛋白酶抑制活性的新型肽化合物及其制备方法。在另一个实施方案中，本发明公开了包含这些肽的药物组合物以及使用它们来治疗与HCV蛋白酶相关的病症的方法。

4.

发明申请
Hybrid polypeptides with selectable properties 有权
标题翻译：具有可选性质的杂交多肽

公开(公告)号：US20060293232A1

公开(公告)日：2006-12-28

申请号：US11206903

申请日：2005-08-17

申请人： Odile Levy , Michael Hanley , Carolyn Jodka , Diana Lewis , Christopher Soares , Soumitra Ghosh , Lawrence D'Souza , David Parkes , Christine Mack

发明人： Odile Levy , Michael Hanley , Carolyn Jodka , Diana Lewis , Christopher Soares , Soumitra Ghosh , Lawrence D'Souza , David Parkes , Christine Mack

IPC分类号： A61K38/22 , C07K14/575

CPC分类号： C07K14/605 , A61K9/0019 , A61K9/19 , A61K38/00 , C07K5/1013 , C07K5/1024 , C07K14/575 , C07K14/58

摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

摘要翻译： 本发明一般涉及可用作治疗和预防代谢性疾病和病症的新颖的可选择的杂交多肽，其可通过控制血浆葡萄糖水平，胰岛素水平和/或胰岛素分泌而减轻，所述胰岛素分泌如糖尿病和糖尿病相关条件。这些病症和障碍包括但不限于高血压，血脂异常，心血管疾病，进食障碍，胰岛素抵抗，肥胖症和任何类型的糖尿病，包括1型，2型和妊娠糖尿病。

5.

发明申请
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus 审中-公开

公开(公告)号：US20060205672A1

公开(公告)日：2006-09-14

申请号：US11241656

申请日：2005-09-30

申请人： Anil Saksena , Viyyoor Girijavallabhan , Raymond Lovey , Edwin Jao , Frank Bennett , Jinping McCormick , Haiyan Wang , Russell Pike , Stephane Bogen , Tin-Yau Chan , Yi-Tsung Liu , Zhaoning Zhu , F. Njoroge , Ashok Arasappan , Tejal Parekh , Ashit Ganguly , Kevin Chen , Srikanth Venkatraman , Henry Vaccaro , Patrick Pinto , Bama Santhanam , Scott Kemp , Odile Levy , Marguerita Lim-Wilby , Susan Tamura , Wanli Wu , Siska Hendrata , Yuhua Huang

发明人： Anil Saksena , Viyyoor Girijavallabhan , Raymond Lovey , Edwin Jao , Frank Bennett , Jinping McCormick , Haiyan Wang , Russell Pike , Stephane Bogen , Tin-Yau Chan , Yi-Tsung Liu , Zhaoning Zhu , F. Njoroge , Ashok Arasappan , Tejal Parekh , Ashit Ganguly , Kevin Chen , Srikanth Venkatraman , Henry Vaccaro , Patrick Pinto , Bama Santhanam , Scott Kemp , Odile Levy , Marguerita Lim-Wilby , Susan Tamura , Wanli Wu , Siska Hendrata , Yuhua Huang

IPC分类号： A61K38/05 , C07K5/06

CPC分类号： C07K5/0202 , A61K38/00 , C07K5/0812 , C07K5/0827 , C07K7/02

摘要： The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

6.

发明申请
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same 有权

公开(公告)号：US20060135747A1

公开(公告)日：2006-06-22

申请号：US11301744

申请日：2005-12-12

申请人： Odile Levy , Carolyn Jodka , Soumitra Ghosh , David Parkes , Richard Pittner , Lawrence D'Souza , John Ahn , Kathryn Prickett , Jonathan Roth , Sean Adams

发明人： Odile Levy , Carolyn Jodka , Soumitra Ghosh , David Parkes , Richard Pittner , Lawrence D'Souza , John Ahn , Kathryn Prickett , Jonathan Roth , Sean Adams

IPC分类号： A61K38/18 , C07K14/475

CPC分类号： C07K14/575 , A61K38/00 , C07K14/475

摘要： The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.

7.

发明申请
Pancreatic polypeptide family motifs and polypeptides comprising the same 失效

公开(公告)号：US20060094653A1

公开(公告)日：2006-05-04

申请号：US11055098

申请日：2005-02-11

申请人： Odile Levy , Carolyn Jodka , Soumitra Ghosh , David Parkes , Richard Pittner , Lawrence D'Souza , John Ahn , Kathryn Prickett

发明人： Odile Levy , Carolyn Jodka , Soumitra Ghosh , David Parkes , Richard Pittner , Lawrence D'Souza , John Ahn , Kathryn Prickett

IPC分类号： A61K38/18 , C07K14/475

CPC分类号： C07K14/575 , A61K38/00 , C07K14/475

摘要： The present invention relates to novel Pancreatic Polypeptide Family (“PPF”) polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50% sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY. Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif. Methods of using the PPF polypeptides of the invention, and pharmaceutical compositions including the PPF polypeptides of the invention are also disclosed.

8.

发明申请
Hybrid polypeptides with selectable properties 审中-公开

公开(公告)号：US20060094652A1

公开(公告)日：2006-05-04

申请号：US11055093

申请日：2005-02-11

申请人： Odile Levy , Michael Hanley , Carolyn Jodka , Diana Lewis , Christopher Soares , Soumitra Ghosh , Lawrence D'Souza , David Parkes , Christine Mack

发明人： Odile Levy , Michael Hanley , Carolyn Jodka , Diana Lewis , Christopher Soares , Soumitra Ghosh , Lawrence D'Souza , David Parkes , Christine Mack

IPC分类号： A61K38/22 , A61K38/23 , A61K38/26

CPC分类号： C07K14/575 , A61K38/00 , C07K5/1013 , C07K5/1024 , C07K7/06 , C07K7/08 , C07K14/57563 , C07K14/595 , C07K2319/00

摘要： The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.